Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
BeOne Medicines
Lyell Immunopharma, Inc.
AVM Biotechnology Inc
BeOne Medicines
Merck Sharp & Dohme LLC
Genmab
Genmab
Debiopharm International SA
Vironexis Biotherapeutics Inc.
AstraZeneca
Hoffmann-La Roche
Galapagos NV
Cho Pharma Inc.
ModeX Therapeutics, An OPKO Health Company
BeOne Medicines
Haihe Biopharma Co., Ltd.
Enterome
Eli Lilly and Company
Hope Biosciences Research Foundation
Acerta Pharma BV
BeOne Medicines
CRISPR Therapeutics
Ipsen
Immunitas Therapeutics
Acerta Pharma BV
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Eisai Inc.
Cyteir Therapeutics, Inc.
Beijing Mabworks Biotech Co., Ltd.
Genmab
Hoffmann-La Roche
Shanghai Blueray Biopharma Co., Ltd.
IGM Biosciences, Inc.
MingSight Pharmaceuticals, Inc
Altor BioScience
Nordic Nanovector
Celgene
Ipsen
BioNova Pharmaceuticals (Shanghai) LTD.
Hoffmann-La Roche
Celgene
SecuraBio
Immune Biosolutions Inc
Asana BioSciences
TCR2 Therapeutics
Atara Biotherapeutics
Hoffmann-La Roche
Alexion Pharmaceuticals, Inc.
Hoffmann-La Roche
Spectrum Pharmaceuticals, Inc